World News

The latest milestone advances the company’s second clinical-stage therapeutic candidate and marks the first clinical programme built using its proprietary Au-HALO™ liver-targeting delivery technology and siRNA platform.

IMPACT Therapeutics received approval from China’s National Medical Products Administration (NMPA) in January 2025 for senaparib as a first-line maintenance therapy for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer.

AbCellera will oversee discovery and early-stage development activities, while Vertex will finance all research and development costs.

Amylyx developed the education initiative after researching the PBH patient community.

eyonis LCS is a Software as a Medical Device that uses AI to assist clinicians in detecting and diagnosing lung cancer during screening workflows.

Under the agreement, MiRecule will combine its NAVIgGator platform, which is designed to support the development of precision RNA medicines, with RBBL’s expertise in peptide discovery, development, and manufacturing.

BYPHAR is designed to simplify raw material selection while helping manufacturers meet increasingly stringent quality and regulatory requirements throughout the development and production process.

Under the agreement, the companies will advance Sail’s lead programme, SAIL-0839, which is being developed to engineer CD4+ and CD8+ T-cells inside the body to treat immune-mediated diseases.

The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary.

The investment will upgrade Resilience’s manufacturing operations in Ohio, where the company has produced Lilly’s Mounjaro and Zepbound since the partners began working together in 2023.